VAL-083: Additional Phase I/II data

Data from 26 patients with refractory GBM in the first 5 cohorts of an open-label, U.S. Phase I/II trial showed that 1.5, 3, 5, 10 and 20 mg/m 2 doses of IV VAL-083 were well tolerated with no treatment-related adverse events or dose-limiting toxicities (DLTs) reported. The MTD has not yet been reached. A 6th cohort is evaluating a 30 mg/m 2 dose of VAL-083. The trial is enrolling GBM patients previously treated with surgery and/or radiation if appropriate and who failed both Avastin bevacizumab and Temodar temozolomide unless contraindicated. Data were presented at the American Association for Cancer Research meeting in San Diego. ...